Molecular Breast Imaging: Clinical Advances and Future Directions
Description
The recently published Appropriate Use Criteria for Molecular Breast Imaging (MBI) by an expert workgroup has identified two clinical scenarios where MBI may serve an important role in the management of breast cancer patients: 1) supplemental screening in women with dense breasts and 2) neoadjuvant therapy response monitoring. These recommendations are a result of both technological advances in the imaging process and the concerted effort of a prospective multiyear, multicenter Density MATTERS trial. This session will present the audience the current landscape, advances, and limitations of anatomical breast imaging with conventional x-ray equipment (i.e, digital mammography and digital breast tomosynthesis) and then explore the role of functional breast imaging with 99mTc-sestamibi MBI in both breast cancer screening and therapy settings.